New approaches might lower drug prices

09/26/2013 | Reuters

Targeted clinical trials, wherein compounds are tested on patients with specific genetic traits, might lower development costs and subsequent prices for promising immunotherapies. Drugmakers are also experimenting with combinations of existing treatments that might cost less than single compounds. The FDA has become more flexible, speeding the approval process for drugs designated as breakthroughs and giving others priority review.

View Full Article in:

Reuters

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Vice President, Idaho Regional Director
PacificSource
Boise, ID